The global point-of-care molecular diagnostics market size was valued at USD 8.69 billion in 2025 and is projected to grow from USD 9.23 billion in 2026 to USD 14.97 billion by 2034, registering a CAGR of 6.23% during the forecast period from 2026 to 2034. North America dominated the point-of-care molecular diagnostics market with a market share of 42.5% in 2025.
The point-of-care molecular diagnostics market is experiencing strong growth driven by the increasing demand for rapid and accurate infectious disease detection across decentralized healthcare settings. Advancements in miniaturized PCR and isothermal technologies are enabling faster turnaround times and improved clinical outcomes. Rising focus on early diagnosis, outbreak preparedness, and personalized treatment is expanding adoption across hospitals, clinics, and home care environments. At the same time, integration of digital connectivity and data-driven diagnostics is enhancing workflow efficiency. Challenges related to cost sensitivity and operational variability persist, yet ongoing innovation in portable platforms and user-friendly assays continues to unlock new opportunities, particularly in emerging markets and remote care delivery systems.
Download a Free Sample To learn more about this report,
Increasing Adoption of Rapid and Portable Molecular Testing Platforms
The point-of-care molecular diagnostics market is moving toward compact testing systems that can deliver molecular results close to the patient without depending entirely on centralized laboratories. Portable PCR platforms, integrated sample-to-result workflows, and cartridge-based systems are improving turnaround times and supporting use across hospitals, urgent care centers, physician offices, decentralized laboratories, and remote healthcare settings.
Growing Integration of Multiplex and Connected Molecular Diagnostic Solutions
Diagnostic platforms are increasingly combining multiplex detection with automated workflows and digital connectivity to provide broader clinical information from a single patient sample. Multiplex molecular testing can differentiate pathogens with overlapping symptoms, while connected systems enable results to be shared with healthcare records and remote-care platforms, improving the speed and coordination of clinical decision-making.
Rising Burden of Infectious Diseases Increases Need for Accessible Molecular Diagnostics
The continued prevalence of respiratory and other infectious diseases is increasing the need for accessible diagnostic solutions across hospitals, outpatient facilities, urgent care centers, and community healthcare settings. Infectious disease outbreaks and the need for timely identification of pathogens are encouraging healthcare systems to strengthen diagnostic capacity and expand access to molecular testing technologies. This underlying clinical need supports continued demand for point-of-care molecular diagnostic platforms.
High Costs of Molecular Diagnostic Systems and Consumables Can Limit Adoption
Point-of-care molecular platforms require investment in analyzers, cartridges, reagents, quality-control procedures, connectivity infrastructure, and operator training. Recurring consumable costs can further increase the total cost of testing, making advanced molecular systems difficult to deploy in healthcare facilities with constrained budgets, particularly in low-resource and emerging markets.
Expansion of Point-of-Care Molecular Diagnostics Across Women's Health and Preventive Screening Creates New Growth Opportunities
The expansion of molecular testing into women's health, sexually transmitted infections, cervical cancer screening, and preventive diagnostics is creating new opportunities beyond traditional infectious disease applications. Self-collection, decentralized screening, and near-patient testing can improve access to molecular diagnostics while enabling faster follow-up and treatment decisions in community and outpatient settings.
Maintaining Accuracy and Regulatory Compliance Across Decentralized Testing Environments Creates Challenges
Expanding molecular diagnostics beyond centralized laboratories requires consistent analytical performance despite differences in operators, sample handling, environmental conditions, and healthcare infrastructure. Manufacturers must demonstrate reliable accuracy while meeting regulatory and quality requirements, making validation, workflow simplification, quality control, and operator training critical to large-scale deployment.
Test Kits Segment is Projected to Register the Fastest Growth at a CAGR of 9.38%
The test kits segment is projected to register the fastest growth at a CAGR of 9.38% during 2026–2034. In 2025, the segment accounted for 46.7% of the global molecular diagnostics market, with a value of USD 4.06 billion. Growth is driven by the increasing demand for rapid and accurate diagnostic testing, rising prevalence of infectious and genetic diseases, and growing adoption of point-of-care testing solutions. Continuous product innovation and expanding access to molecular diagnostic services are expected to further support the segment's growth.
The analyzers segment continues to maintain a significant market presence owing to their essential role in automating molecular diagnostic workflows and improving laboratory efficiency. Increasing investments in advanced laboratory infrastructure and high-throughput testing capabilities continue to support demand for analyzers. The reagents segment is witnessing steady growth due to their recurring use in molecular testing procedures and the growing volume of diagnostic tests performed across healthcare facilities.
Request Customizationto receive a tailored report.
Genetic Sequencing Segment is Projected to Register the Fastest Growth at a CAGR of 10.24%
The genetic sequencing segment is projected to register the fastest growth at a CAGR of 10.24% during 2026–2034. In 2025, the segment accounted for 17.2% of the global molecular diagnostics market, with a value of USD 1.49 billion. Growth is driven by increasing adoption of precision medicine, expanding applications in cancer diagnostics, and continuous advancements in next-generation sequencing technologies. Rising investments in genomic research and personalized healthcare are expected to further accelerate the segment's growth.
The PCR segment dominated the market owing to its high sensitivity, accuracy, and widespread use in detecting infectious diseases, genetic disorders, and cancer biomarkers. The hybridization segment continues to witness stable demand due to its application in genetic analysis and disease identification, while the microarray segment remains an important technology for large-scale gene expression profiling, biomarker discovery, and research applications.
Homecare Segment is Projected to Register the Fastest Growth at a CAGR of 10.31%
The homecare segment is projected to register the fastest growth at a CAGR of 10.31% during 2026–2034. In 2025, the segment accounted for 14.7% of the global molecular diagnostics market, with a value of USD 1.28 billion. Growth is driven by increasing demand for convenient diagnostic solutions, rising adoption of self-testing kits, and growing awareness of early disease detection. Technological advancements in portable molecular diagnostic devices are expected to further support the expansion of home-based testing.
The hospital segment dominated the market owing to the high volume of diagnostic testing, availability of advanced laboratory infrastructure, and access to skilled healthcare professionals for accurate disease diagnosis and treatment planning. The decentralized laboratories segment continues to witness strong demand as healthcare providers increasingly adopt distributed testing models to improve accessibility and reduce turnaround times.
The assisted living healthcare facilities segment is expanding steadily due to the growing elderly population and increasing need for routine diagnostic monitoring in long-term care settings. Rising emphasis on timely disease detection and personalized patient care continues to support the adoption of molecular diagnostic technologies in these facilities.
Speak to an Analystto discuss market opportunities.
North America point-of-care molecular diagnostics market accounted for 42.5% of the global market, reaching USD 3.69 billion in 2025, and is projected to grow at a CAGR of 8.42% during the forecast period. The market is driven by increasing demand for rapid diagnostic testing, growing prevalence of infectious diseases, expanding adoption of decentralized healthcare, and continuous advancements in molecular diagnostic technologies. Strong healthcare infrastructure and favorable reimbursement policies continue to support regional market growth.
The US market was valued at USD 3.14 billion in 2025, making it the largest contributor in North America. Rising demand for rapid molecular testing, increasing adoption of point-of-care diagnostic platforms, expanding investments in precision medicine, and continuous technological innovation continue to drive market growth.
Canada's market reached USD 0.55 billion in 2025. Growing healthcare investments, increasing adoption of portable diagnostic systems, expanding infectious disease screening programs, and rising demand for early disease detection continue to support steady market expansion.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe point-of-care molecular diagnostics market accounted for 27.3% of the global market, reaching USD 2.37 billion in 2025, and is projected to grow at a CAGR of 8.11% during the forecast period. Increasing demand for rapid and accurate diagnostic solutions, expanding healthcare infrastructure, growing focus on personalized medicine, and supportive regulatory frameworks continue to strengthen regional market growth.
The UK market was valued at USD 0.47 billion in 2025. Rising adoption of molecular diagnostic technologies, increasing investments in healthcare modernization, expanding disease surveillance programs, and growing demand for decentralized testing continue to support market growth.
Germany market accounted for USD 0.66 billion in 2025. Strong diagnostic manufacturing capabilities, increasing research in molecular diagnostics, expanding use of rapid testing platforms, and advanced healthcare infrastructure continue to drive market expansion.
Asia Pacific point-of-care molecular diagnostics market accounted for 21.6% of the global market, reaching USD 1.88 billion in 2025, and is projected to grow at a CAGR of 10.86% during the forecast period. Rising healthcare expenditure, increasing awareness of early disease diagnosis, expanding healthcare infrastructure, and growing demand for rapid molecular testing continue to accelerate regional market growth. Government initiatives to improve diagnostic accessibility further support market expansion.
Japan's market generated USD 0.34 billion in 2025. Increasing demand for advanced diagnostic technologies, expanding precision medicine initiatives, growing aging population, and continuous innovation in healthcare continue to support market growth.
China's market accounted for USD 0.79 billion in 2025, representing the largest share within Asia Pacific. Expanding healthcare infrastructure, increasing domestic production of molecular diagnostic devices, growing disease screening programs, and rising healthcare investments continue to drive market expansion.
Latin America point-of-care molecular diagnostics market accounted for 5.1% of the global market, reaching USD 0.44 billion in 2025, and is projected to grow at a CAGR of 8.73% during the forecast period. Rising healthcare investments, increasing adoption of rapid diagnostic technologies, expanding laboratory infrastructure, and growing awareness of early disease detection continue to support regional market growth.
Brazil market accounted for USD 0.24 billion in 2025. Growing investments in healthcare infrastructure, increasing demand for portable diagnostic systems, expanding infectious disease testing, and rising adoption of molecular diagnostic technologies continue to support market expansion.
Middle East & Africa point-of-care molecular diagnostics market accounted for 3.5% of the global market, totaling USD 0.30 billion in 2025, and is projected to grow at a CAGR of 7.96% during the forecast period. Increasing investments in healthcare infrastructure, expanding access to rapid diagnostic technologies, growing disease surveillance initiatives, and rising awareness of early diagnosis continue to support regional market growth.
The UAE market was valued at USD 0.07 billion in 2025. Rising investments in advanced healthcare technologies, expanding diagnostic laboratory capabilities, increasing demand for rapid testing solutions, and growing healthcare modernization initiatives continue to drive market growth.
Africa's market reached USD 0.23 billion in 2025. Improving access to healthcare services, expanding infectious disease screening programs, increasing investments in diagnostic infrastructure, and growing adoption of portable molecular testing technologies continue to create long-term growth opportunities across the region.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Asia Pacific Electrocardiograph (ECG) Market Size, Share Trend Analysis by 2034
Middle East and Africa Dental Intraoral Scanners Market Size, 2034
Artificial Lung Market Size, Share, Growth, Analysis, 2034
Bronchoscopes Market Size, Share, Growth, Analysis, Report, 2034
Aesthetic Threads Market Size, Share, Growth, Forecast, 2034
Middle East And Africa Diabetes Devices Market Size and Forecast 2034
We are featured on:
sales@straitsresearch.com